Roger J. Waltzman - 15 Feb 2023 Form 4 Insider Report for Molecular Templates, Inc.

Reporting relationship: Chief Medical Officer
Issuer ticker: N/A
Reported as of: 15 Feb 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Feb 2023, 07:00:14 UTC
Prior SEC filing: 17 Feb 2022
Next SEC filing: 07 Aug 2023
Source filing: View source filing
Reporting owner signature: /s/ Roger J. Walztman

Key filing fact

Roger J. Waltzman filed Form 4 for Molecular Templates, Inc. on 17 Feb 2023.

Key facts

This page summarizes Roger J. Waltzman's Form 4 filing for Molecular Templates, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 17 Feb 2023, 07:00.

Change

Previous filing in this sequence was filed on 17 Feb 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MTEM transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +170,000
Change %
Price: $0.000000
Shares after: 170,000
Date: 15 Feb 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 170,000
Exercise price: $0.4812
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the shares subject to the option shall vest on February 15, 2024, and thereafter, the remaining 75% of the shares subject to the option shall vest pro rata on a monthly basis over the following 36 months.

SEC remarks

Chief Medical Officer